KRAS and non-small cell lung carcinoma: In lung cancer (non-small cell lung cancer), the common KRAS mutation is the KRAS G12C (glycine mutated into cysteine) and, importantly, two inhibitors have been developed: sotorasib [145,146] and adagrasib, both of which FDA approved [147].